Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Xilio Therapeutics Q3 2026 Results: Net Loss of $5.95M, Loss Narrows

Xilio Therapeutics reported 7,063,982 shares of common stock outstanding as of November 6, 2026. The company highlights its reliance on strategic collaborations with AbbVie and Gilead, and notes potential gross proceeds of $36.2 million in Q4 2026 from the exercise of Series C warrants.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue10.019.1
Net income-5.9-16.3
EPS (diluted, $ a share)$-0.30$-1.58

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-47.6%
Operating margin-117.7%
Source

10-Q filed with the SEC, NASDAQ: XLO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Xilio Therapeutics, Inc.: key numbers

Share price
$7.70Close, Nov 16
Market cap
$54.4M
Shares outstanding
7.06MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Xilio Therapeutics, Inc.

All →
7:35 AM ET 8-K
Financial Results

Xilio Therapeutics Financial Results

Xilio Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting the dosing of the first patient in its Phase 1/2 trial for XTX501. The company ended the quarter with $45.1 million in cash and cash equivalents, which it expects will fund operations into the second quarter of 2027.

Term
Q3 2026

“In the third quarter, we initiated our Phase 1/2 clinical trial for XTX501, a PD-1/masked IL-2 bispecific that we believe has the potential to become a foundational backbone immunotherapy regimen for solid tumors.”

René Russo, Pharm.D., president and chief executive officer of Xilio

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.